Literature DB >> 36068477

Pharmacogenomics in Children.

Michael J Rieder1, Abdelbaset A Elzagallaai2.   

Abstract

Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of children's research have made pharmacogenomic assessment for children much easier to pursue. It is likely that pharmacogenomics will become part of the therapeutic decision-making process for children, notably in areas such as childhood cancer where weighing benefits and risks of therapy is crucial.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Childhood cancer; Children; Drug ontogeny; Drug safety; Genetics; Pharmacogenomics; Pharmacology

Mesh:

Year:  2022        PMID: 36068477     DOI: 10.1007/978-1-0716-2573-6_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  141 in total

1.  Off-label use of drugs in Italy: a prospective, observational and multicentre study.

Authors:  C Pandolfini; P Impicciatore; D Provasi; F Rocchi; R Campi; M Bonati
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

2.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

3.  Sir Archibald Garrod's inborn errors of metabolism. I. Cystinuria.

Authors:  W E KNOX
Journal:  Am J Hum Genet       Date:  1958-03       Impact factor: 11.025

4.  Researchers' perceptions of the ethical implications of pharmacogenomics research with children.

Authors:  D Avard; T Silverstein; G Sillon; Y Joly
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

Review 5.  Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature.

Authors:  Jennifer Mason; Munir Pirmohamed; Tony Nunn
Journal:  Eur J Clin Pharmacol       Date:  2011-07-22       Impact factor: 2.953

6.  Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study.

Authors:  Andrea D Pratico; Laura Longo; Silvana Mansueto; Lucia Gozzo; Ignazio Barberi; Venera Tiralongo; Vincenzo Salvo; Raffaele Falsaperla; Giovanna Vitaliti; Mario La Rosa; Salvatore Leonardi; Antonio Rotondo; Nicoletta Avola; Debora Sgarlata; Annalisa Damiano; Massimo Tirantello; Gaspare Anzelmo; Domenico Cipolla; Angelo Rizzo; Antonio Russo; Martino Ruggieri; Salvatore Salomone; Filippo Drago
Journal:  Curr Drug Saf       Date:  2018

7.  Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.

Authors:  Lucila I Castro-Pastrana; Bruce C Carleton
Journal:  J Popul Ther Clin Pharmacol       Date:  2011-03-21

Review 8.  A literature review on off-label drug use in children.

Authors:  Chiara Pandolfini; Maurizio Bonati
Journal:  Eur J Pediatr       Date:  2005-05-24       Impact factor: 3.183

9.  Off-label prescribing in pediatric outpatients.

Authors:  Aurore Palmaro; Raphael Bissuel; Nicholas Renaud; Geneviève Durrieu; Brigitte Escourrou; Stephane Oustric; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Pediatrics       Date:  2014-12-15       Impact factor: 7.124

Review 10.  Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Authors:  Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.